Mohamad Faizal Bin Ramli/iStock via Getty Images By Jennifer Nash The Federal Reserve’s preferred inflation gauge, the core PCE price index, climbed 3.2% year-over-year in March. This marks the highest level since November 2023 and confirms a steady pickup from February’s 3.0% reading. On a monthly basis, core prices rose 0.3%. The headline index surged 3.5% year-over-year, marking its highest lev...
Mohamad Faizal Bin Ramli/iStock via Getty Images By Jennifer Nash The Federal Reserve’s preferred inflation gauge, the core PCE price index, climbed 3.2% year-over-year in March. This marks the highest level since November 2023 and confirms a steady pickup from February’s 3.0% reading. On a monthly basis, core prices rose 0.3%. The headline index surged 3.5% year-over-year, marking its highest level since May 2023. This acceleration was driven largely by a 0.7% monthly jump, the largest single-month increase since 2022 and reflecting a significant spike in global energy costs. All annual and monthly figures came in as expected. Understanding the PCE Price Index Personal consumption expenditures (PCE) track the actual spending habits (personal consumption) of domestic consumers. The headline number includes all categories, capturing the immediate "sticker shock" felt by households at the pump and grocery store. Core PCE excludes food and energy, making it less volatile than the headline PCE, and thus provides a clearer view of long-term inflation trends. The adjacent thumbnail gives us a close-up of the trend in YoY core PCE since January 2012. The first string of red data points highlights the 12 consecutive months when core PCE hovered in a narrow range around its interim low. The second string highlights the lower range from late 2014 through 2015. Core PCE shifted higher in 2016 with a decline in 2017, 2019, and 2020, with a major jump in 2022. The following chart illustrates the monthly year-over-year changes since 2000, with the 2% benchmark highlighted as the Fed's ultimate target. For a long-term perspective, here are the same two metrics spanning five decades. Inflation: The Fed's 2% Target The Federal Reserve concluded its third meeting of the year by maintaining the federal funds rate at 3.50%–3.75% . The decision, which markets had fully priced in, keeps the benchmark rate at its lowest level since November 2022 for the third meeting in a row. However, th...
Viavi Solutions (NASDAQ: VIAV) was a quick solution to ailing stock portfolios on Thursday. The tech equipment specialist published its latest quarterly earnings report, which featured not only beats on trailing results but on current-quarter guidance. That led to something of a bull run on the stock, which closed the day more than 15% higher in price. After market close Wednesday, Viavi reported ...
Viavi Solutions (NASDAQ: VIAV) was a quick solution to ailing stock portfolios on Thursday. The tech equipment specialist published its latest quarterly earnings report, which featured not only beats on trailing results but on current-quarter guidance. That led to something of a bull run on the stock, which closed the day more than 15% higher in price. After market close Wednesday, Viavi reported net revenue of just under $407 million for its third quarter of fiscal 2026. That was nearly 43% higher year over year and easily beat the consensus analyst estimate of nearly $394 million. Image source: Getty Images. Continue reading
Following a pivotal 2025 investment from CoreWeave and AMD, CHAI AI has maintained an unstoppable growth trajectory, surpassing $80 million ARR at the close of Q1 2026, propelling the company to an estimated $2.4 billion valuation.
Following a pivotal 2025 investment from CoreWeave and AMD, CHAI AI has maintained an unstoppable growth trajectory, surpassing $80 million ARR at the close of Q1 2026, propelling the company to an estimated $2.4 billion valuation.
Seaport Therapeutics Inc. , a clinical-stage biotechnology company focused on antidepressants and anxiety drugs, raised nearly $255 million in an upsized US initial public offering that priced at the top of its marketed range, according to people familiar with the matter. The neuro-psychiatry company sold 14.6 million shares at $18 each, the people said, asking not to be identified as the informat...
Seaport Therapeutics Inc. , a clinical-stage biotechnology company focused on antidepressants and anxiety drugs, raised nearly $255 million in an upsized US initial public offering that priced at the top of its marketed range, according to people familiar with the matter. The neuro-psychiatry company sold 14.6 million shares at $18 each, the people said, asking not to be identified as the information isn’t public. The biotech firm had offered 11.8 million shares for $16 to $18 each, its filings show. A representative for Seaport didn’t immediately respond to a request for comment. Founded in 2024, the clinical-stage company is developing therapies to treat patients with major depressive disorder and generalized anxiety disorder. The company, which is backed by PureTech Health Plc , had a net loss of $74.9 million last year, compared with a net loss of $46.9 million a year earlier, according to the filings. Nasdaq and London Stock Exchange-listed PureTech’s stake is expected to decline to 33% after the offering from 43%, the filings show. Affiliates of Arch Ventures Partners will have a 10% stake, down from 13%, and General Atlantic is set to have 6.6%, down from 8.6%. For the latest news on equity capital markets activity in the US, Canada and Latin America, follow the channel or visit NI BFWECMUS . To subscribe to ECM Watch , Bloomberg’s daily roundup of news from around the region, click here . The offering is being led by Goldman Sachs Group Inc. , JPMorgan Chase & Co. , Leerink Partners , Citigroup Inc. and Stifel Financial Corp. The shares are expected to trade on the Nasdaq Global Market under the symbol SPTX.